Voydeya approved in EU for enhanced treatment of PNH with residual haemolytic anaemia

Voydeya (danicopan), a first-in-class oral Factor D inhibitor from Alexion, AstraZeneca Rare Disease, has received approval from the European Commission as an add-on treatment to ... Read More